Avanir cites 'encouraging' progress in PhIII program for Alzheimer's agitation
Avanir Pharma has chalked up a win for the first late-stage study for AVP-786 in Alzheimer’s agitation, laying the groundwork for a high-risk, high-reward Phase III program.
The Otsuka subsidiary kept things general, divulging only that one of the two doses tested in the study induced a significant improvement for patients with moderate-to-severe agitation on the Cohen-Mansfield Agitation Inventory; in the other dose arm, improvement was “numerical but not significant.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.